



# Press Release

## AMP Therapeutics receives SAB grant

*Leipzig (Germany), October 25, 2012* – FOR IMMEDIATE RELEASE

AMP Therapeutics GmbH of Leipzig, Germany reported that it has been awarded an R&D grant from the SAB State Bank of Saxony. In a joint project with the University of Leipzig titled "Use of antimicrobial peptides as new chemotherapy agents" the partners will collaborate on this project with a total cost volume of € 1.9 m. The non-repayable grant provided by the SAB makes up € 1.7 m of the total sum.

The funds will be used to support AMPT's R&D programs. In particular, the financing will support the development of AMPT'S product pipeline, including lead compounds developed from antimicrobial peptides found in insects such as the honeybee and certain bugs.

Marc W. Hentz, Managing Director responsible for Finances and Business Development commented: "As a native Saxonian company we are proud to receive support from a strong local partner such as the SAB. In the three years since our inception we have found Saxony to be an excellent environment place for Life Science firms and hope to contribute to that further with our collaboration."

"We believe this non-dilutive financing validates the concept of AMPT's proprietary and innovative approach to developing a novel class of drugs to treat serious bacterial infections," said Knut Adermann, Managing Director responsible for Research and Development.

### **About AMP Therapeutics (AMPT)**

AMP Therapeutics was founded in 2009 as a spin-off from Prof. Ralf Hoffmann's laboratory at the University of Leipzig and is based in the Center for Biotechnology and Biomedicine at BIO CITY in Leipzig, Germany. First round investors in 2011 were the Boehringer Ingelheim Venture Fund and the Novartis Venture Fund. AMPT is engaged in the discovery and commercialization of new medicines for the treatment of severe bacterial infections predominantly caused by drug-resistant Gram-negative bacteria. Infections caused by drug-resistant pneumonia, bloodstream infections, surgical site infections and urinary tract infections represent a major global health threat with an unfavorable prognosis and are largely untreatable with existing antibiotics. AMPT addresses this significant unmet medical need by advancing the preclinical and clinical development of its proprietary antibacterial compounds. AMPT's technology is based on naturally occurring antimicrobial peptides found across various species.

[www.amp-therapeutics.com](http://www.amp-therapeutics.com)

Contact: Dr. Marc W. Hentz, Managing Director AMP Therapeutics GmbH

[info@amp-therapeutics.com](mailto:info@amp-therapeutics.com)